Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 333.33 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $13.54 million which beat the analyst consensus estimate of $12.68 million by 6.80 percent. This is a 4.15 percent increase over sales of $13.00 million the same period last year.